Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 47

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 47
---
; |

| • | our receipt of regulatory approvals for our therapeutic candidates, and the timing of other regulatory filings and approvals; |

| • | the clinical development, commercialization, and market acceptance of our therapeutic candidates, including the degree and pace of market uptake of APHEXDA; |

| • | whether access to APHEXDA is achieved in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party payors; |

| • | our ability to establish, manage, and maintain corporate collaborations, as well as the ability of our collaborators to execute on their development and commercialization plans; |

| • | our ability to integrate new therapeutic candidates and new personnel; |

| • | the interpretation of the properties and characteristics of our therapeutic candidates and of the results obtained with our therapeutic candidates in preclinical studies or clinical trials; |

| • | the implementation of our business model and strategic plans for our business and therapeutic candidates; |

| • | the scope of protection that we are able to establish and maintain for intellectual property rights covering our therapeutic candidates and our ability to operate our business without infringing the 
 intellectual property rights of others;                                                                                                                                                                |

| • | estimates of our expenses, future revenues, capital requirements and our need for and ability to access sufficient additional financing, including any unexpected costs or delays in the ongoing commercial 
 launch of APHEXDA;                                                                                                                                                                                          |

| • | risks related to changes in healthcare laws, rules, and regulations in the United States or elsewhere; |

| • | competitive companies, technologies, and our industry; |

| • | statements as to the impact of the political and security situation in Israel on our business, including the impact of Israel’s war with Hamas and other militant groups, which may exacerbate the magnitude 
 of the factors discussed above.                                                                                                                                                                              |

We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in Item 3.D. – “Risk Factors” in our most recent Annual Report on Form 20-F, or any updates in our Reports on Form 6-K. Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements attributable to us or to any person acting on our behalf speak only as of the date here